<code id='53535BBF26'></code><style id='53535BBF26'></style>
      • <acronym id='53535BBF26'></acronym>
      <center id='53535BBF26'><center id='53535BBF26'><tfoot id='53535BBF26'></tfoot></center><abbr id='53535BBF26'><dir id='53535BBF26'><tfoot id='53535BBF26'></tfoot><noframes id='53535BBF26'>
      • <optgroup id='53535BBF26'><strike id='53535BBF26'><sup id='53535BBF26'></sup></strike><code id='53535BBF26'></code></optgroup>
        5. <b id='53535BBF26'><label id='53535BBF26'><select id='53535BBF26'><dt id='53535BBF26'><span id='53535BBF26'></span></dt></select></label></b><u id='53535BBF26'></u>
          <i id='53535BBF26'><strike id='53535BBF26'><tt id='53535BBF26'><pre id='53535BBF26'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / entertainment / fashion      
           
     
           
      
          fashion 
           
      
           
      
           
       2025-10-02 19:30:22 
   
      
           
      
           
                        
          fashion  
          
                                   
                 
                                      author：Wikipedia   
                                        
                                      
                                      Page View：4
                                  
                                    
          
                                   
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe
          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 
          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?
          advertisement
          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          NIH chief: government has fallen behind pharma on clinical trials
                                
                            
          Next article：  
                                      
                                          Hollywood unions extend contract negotiations for actors
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles